Exodus Point Capital Management, LP Aprea Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

$14.7 Billion
Q2 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 13, 2022	SELL	$1.59 - $3.16 $27,548 - $54,750	-17,326 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$2.87 - $5.58 $49,725 - $96,679	17,326 New	17,326 $50,000
Q2 2021 Aug 16, 2021	SELL	$4.05 - $5.5 $49,920 - $67,793	-12,326 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.73 - $8.15 $58,301 - $100,456	12,326 New	12,326 $63,000
Q2 2020 Aug 14, 2020	SELL	$25.47 - $39.69 $153,380 - $239,013	-6,022 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$31.65 - $45.3 $190,596 - $272,796	6,022 New	6,022 $209,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,454
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.